Parabilis Medicines Inc., a clinical-stage cancer drug developer, raised nearly $745 million in an upsized US initial public offering that priced above its marketed range, and a private placement.

Two college football players sued the NCAA and four major athletic conferences in a proposed class action Tuesday, claiming ...

The top Democrat on the House tax writing panel says he’s in no rush to enact bipartisan cryptocurrency tax legislation, even ...

House lawmakers passed a bill that would impose strict bargaining timelines for employers and labor groups when negotiating a ...

A federal appeals court on Tuesday appeared open to claims that the FDA failed to go through notice-and-comment procedures ...

A federal Maryland judge refused to dismiss a second surprise medical billing case, further cracking open the door to doctors ...

A Chicago federal prosecutor walked into a grand jury room last fall with apparent confidence, telling grand jurors she was ...

A New York parking management company unlawfully refused to hire unionized valet attendants who worked for the company that ...

Celebrity tattoo artist Kat Von D’s appellate win in a copyright suit over her use of a photographer’s Miles Davis portrait ...

The EPA’s first effort to use an emerging type of scientific data to calculate the amount of a chemical that is hazardous ...

Amazon.com Inc.’s challenge to an historic union win at a New York City warehouse will remain in the Fifth Circuit after a ...

The artwork of Carmen Herrera, an abstract artist who died in 2022 at the age of 106, was incorrectly overvalued by the IRS ...